CN103002909B - 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途 - Google Patents

包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途 Download PDF

Info

Publication number
CN103002909B
CN103002909B CN201180017201.7A CN201180017201A CN103002909B CN 103002909 B CN103002909 B CN 103002909B CN 201180017201 A CN201180017201 A CN 201180017201A CN 103002909 B CN103002909 B CN 103002909B
Authority
CN
China
Prior art keywords
vsp
antigen
polypeptide
protein
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180017201.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103002909A (zh
Inventor
D·克拉茨曼
E·皮亚乔
H·卢简
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NICOLAY RENAUD
Consejo Nacional de Investigaciones Cientificas y Tecnicas CONICET
Universidad Catolica de Cordoba UCC
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Consejo Nacional de Investigaciones Cientificas y Tecnicas CONICET
Universidad Catolica de Cordoba UCC
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Universite Pierre et Marie Curie
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional de Investigaciones Cientificas y Tecnicas CONICET, Universidad Catolica de Cordoba UCC, NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris APHP filed Critical Consejo Nacional de Investigaciones Cientificas y Tecnicas CONICET
Publication of CN103002909A publication Critical patent/CN103002909A/zh
Application granted granted Critical
Publication of CN103002909B publication Critical patent/CN103002909B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201180017201.7A 2010-03-29 2011-03-29 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途 Expired - Fee Related CN103002909B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305317 2010-03-29
EP10305317.9 2010-03-29
PCT/EP2011/054866 WO2011120994A1 (en) 2010-03-29 2011-03-29 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof

Publications (2)

Publication Number Publication Date
CN103002909A CN103002909A (zh) 2013-03-27
CN103002909B true CN103002909B (zh) 2016-06-29

Family

ID=42312972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180017201.7A Expired - Fee Related CN103002909B (zh) 2010-03-29 2011-03-29 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途

Country Status (12)

Country Link
US (1) US9801927B2 (enExample)
EP (2) EP3156068B1 (enExample)
JP (1) JP5942296B2 (enExample)
KR (1) KR101866301B1 (enExample)
CN (1) CN103002909B (enExample)
AR (1) AR081809A1 (enExample)
BR (1) BR112012024872B1 (enExample)
CA (1) CA2792174C (enExample)
ES (1) ES2619077T3 (enExample)
SG (1) SG183977A1 (enExample)
UY (1) UY33297A (enExample)
WO (1) WO2011120994A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
WO2009101204A2 (en) * 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
US9248171B2 (en) * 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
WO2009101206A2 (en) * 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
RU2615460C2 (ru) 2010-11-25 2017-04-04 Имнейт Сарл Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов. используемых для генной терапии или генной вакцинации
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するｂ型肝炎ウイルス様粒子結晶
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) * 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20240015731A (ko) 2016-04-19 2024-02-05 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
EP4144752A1 (en) * 2021-09-02 2023-03-08 Sorbonne Universite Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034893A2 (en) * 2000-10-26 2002-05-02 Genopoïetic Synthetic viruses and uses thereof
WO2006093516A2 (en) * 2004-06-22 2006-09-08 The Regents Of The University Of California Peptide-coated nanoparticles with graded shell compositions
WO2008094197A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165469A (en) * 1988-01-13 2000-12-26 University Of Virginia Recombinant Entamoeba histolytica lectin subunit peptides and reagents specific for members of the 170 kD subunit multigene family
DE60041042D1 (de) * 1999-03-12 2009-01-22 Aventis Pasteur Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
EP2392345A3 (en) 2002-07-18 2012-03-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
DE502004010408D1 (de) 2004-07-02 2009-12-31 Schoelly Fiberoptic Gmbh Vorrichtung und verwendung der vorrichtung zur aufnahme und verarbeitung eines bildes
WO2006026746A2 (en) 2004-08-31 2006-03-09 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to separate and expand antigen-specific t cells
GB0426641D0 (en) * 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
WO2007122388A2 (en) 2006-04-13 2007-11-01 Midatech Limited Nanoparticles containing three various ligands for providing immune responses against infectious agents
PT2476435T (pt) * 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
EP2199301A1 (en) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034893A2 (en) * 2000-10-26 2002-05-02 Genopoïetic Synthetic viruses and uses thereof
WO2006093516A2 (en) * 2004-06-22 2006-09-08 The Regents Of The University Of California Peptide-coated nanoparticles with graded shell compositions
WO2008094197A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Conformationally correct expression of membrane-anchored Toxoplasma gondii SAG1 in the primitive protozoan Giardia duodenalis;Matthias Marti et al;《INFECTION AND IMMUNITY》;20021231;第70卷(第2期);全文 *
Protective Immunity against Streptococcus mutans Infection in Mice after Intranasal Immunization with the Glucan-Binding Region of S. mutans Glucosyltransferase;CHRISTINA JESPERSGAARD et al;《INFECTION AND IMMUNITY》;19991231;第67卷(第12期);全文 *
Systemic and Local Antibody Response in Mice Induced by a Recombinant Peptide Fragment from Giardia Zamblia Variant Surface Protein (VSP) H7 Produced by a Salmonella typhimwium Vaccine Strain;S. STAGER, B. GOTTSTEIN et al;《Intemnarionoi Journal for Parasilology》;19971231;第27卷(第8期);摘要、第968页右栏第2段 *

Also Published As

Publication number Publication date
CA2792174C (en) 2019-09-24
KR20130063497A (ko) 2013-06-14
CA2792174A1 (en) 2011-10-06
UY33297A (es) 2011-09-30
KR101866301B1 (ko) 2018-06-11
BR112012024872B1 (pt) 2022-01-11
JP2013523686A (ja) 2013-06-17
EP2552476A1 (en) 2013-02-06
JP5942296B2 (ja) 2016-06-29
CN103002909A (zh) 2013-03-27
EP2552476B1 (en) 2016-12-07
AR081809A1 (es) 2012-10-24
EP3156068B1 (en) 2021-11-03
US9801927B2 (en) 2017-10-31
EP3156068A1 (en) 2017-04-19
WO2011120994A1 (en) 2011-10-06
US20130095133A1 (en) 2013-04-18
BR112012024872A2 (enExample) 2017-08-15
SG183977A1 (en) 2012-10-30
ES2619077T3 (es) 2017-06-23

Similar Documents

Publication Publication Date Title
CN103002909B (zh) 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
CN111375055B (zh) 一种2019-nCoV亚单位疫苗组合物及其免疫方法
CN104144941B (zh) 以计算方式优化的人和禽h5n1流感的广泛反应性抗原
JPH09508622A (ja) Ｄｎａ転写ユニットの接種による免疫化
WO2022135563A1 (zh) 同时诱导抗多种病毒的免疫应答的方法
US12397050B2 (en) Universal mammalian influenza vaccine
US7235245B2 (en) Chimeric lyssavirus nucleic acids and polypeptides
CA2370278C (en) Chimeric lyssavirus nucleic acids and polypeptides
US20240366753A1 (en) Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus
US20230414763A1 (en) Transmucosal amphiphile-protein conjugate vaccine
WO2025189435A1 (zh) 针对猫fipv的多表位抗原构建rna疫苗的方法
EP1721982B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
HK1098952A (en) Antigen delivery system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CENTRO NACIONAL DE INVESTIGACIONES CIENTIFICAS

Free format text: FORMER OWNER: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALS (INSERM)

Effective date: 20140909

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140909

Address after: Paris France

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant after: NICOLAY RENAUD

Applicant after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant after: CONICET CONSEJO NAC DE INVESTIGACIONES CIENTIFICAS Y TECN

Applicant after: UNIVERSIDAD CATOLICA DE CORDOBA

Address before: Paris France

Applicant before: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant before: NICOLAY RENAUD

Applicant before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant before: CONICET CONSEJO NAC DE INVESTIGACIONES CIENTIFICAS Y TECN

Applicant before: UNIVERSIDAD CATOLICA DE CORDOBA

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160629

CF01 Termination of patent right due to non-payment of annual fee